Previous 10 | Next 10 |
BAUDETTE, Minn. , Oct. 2, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Aspirin and Extended Release Dipyridamole Capsules, 25mg/200mg (the generic equivalent of Aggrenox®). This launch represents ANI's fifth generic product...
ANI Pharmaceuticals (NASDAQ: ANIP ) initiated with Buy rating and $76 (9% upside) price target at Guggenheim. More news on: ANI Pharmaceuticals, Inc., Agios Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
BAUDETTE, Minn. , Sept. 11, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Vancomycin HCl for Oral Solution, 250mg per 5mL (the generic equivalent to ANI's Vancocin® for Oral Solution). To facilitate ease of adminis...
U.S. Senator Bernie Sanders (I-VT) and Representative Elijah Cummings (D-MD - 7th district) have launched an investigation targeting Teva Pharmaceutical Industries ( TEVA -8% ), Mylan N.V. ( MYL -7.8% ) and Heritage Pharmaceuticals for allegedly obstructing a Congressional inquiry into...
ANI Pharmaceuticals, Inc. (ANIP) Q2 2019 Earnings Conference Call August 07, 2019, 10:30 ET Company Participants Arthur Przybyl - President, CEO & Director Stephen Carey - CFO & VP of Finance Conference Call Participants Elliot Wilbur - Raymond James & Associates ...
ANI Pharmaceuticals ( ANIP -13.8% ) Q2 results : Revenues: $54.4M (+15.0%); Generic pharmaceutical products: $36.3M (+20.2%); Branded pharmaceutical products: $14M (+33.3%); Contract manufacturing: $3.7M (+117.6%); Royalty and other: $0.4M (-91.8%). More news on: ANI Pharmaceuticals, In...
ANI Pharmaceuticals (NASDAQ: ANIP ): Q2 Non-GAAP EPS of $1.44 beats by $0.16 ; GAAP EPS of $0.53 beats by $0.01 . More news on: ANI Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
BAUDETTE, Minn. , Aug. 7, 2019 /PRNewswire/ -- For the second quarter 2019: Net revenues of $54.4 million , an increase of 15% versus prior year GAAP net income of $6.6 million and diluted GAAP earnings per share of $0.53 , increases of 137% and 130% versus prior year, res...
AMAG , ANIP , ATHM , ATKR , AVA , BCOR , BV , CNP , CORE , CPRI , CSTE , CVS , CYBR , DNR , DOC , ETM , EVOP , FUN , GOLF , GTN , HL , HZNP , ICPT , INGN , INXN , IONS , JELD , KELYA , LAMR , LL , LXP , MFA , MIDD , NRG , NVMI , NXST , NYT , ODP , OMI ...
BAUDETTE, Minn. , July 31, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its second quarter and year-to-date 2019 financial results on Wednesday, August 7, 2019 , before the opening of the U.S. financial markets. The earni...
News, Short Squeeze, Breakout and More Instantly...
ANI Pharmaceuticals Inc. Company Name:
ANIP Stock Symbol:
NASDAQ Market:
ANI Pharmaceuticals Inc. Website:
PRINCETON, N.J., July 15, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), the Company launched L-Glutamine Oral Po...
2024-07-09 17:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
PRINCETON, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) and launched Naproxen Delayed-Release Tablets, USP....